

CONITEC in Action: A Trend Analysis of CONITEC’s SUS Incorporation Outcomes from 2020 to Present Day

Dominika Meszarosova, Daniel Tito Bacheschi | Evidence Solutions: Consulting, Precision AQ

For further information, contact Dominika.Mezzarosova@precisionaq.com or visit us on <https://www.precisionaq.com>

INTRODUCTION

- Presenting a unique public-private dual marketplace, Brazil’s healthcare landscape is heavily shaped by its public HTA evaluation body (CONITEC)
- CONITEC directly informs the Ministry of Health’s SUS incorporation decisions for new and existing health technologies.

OBJECTIVE

- The research presented here aims to provide insights into trends in CONITEC’s incorporation outcomes from 2020 to present day via publicly available decision data

METHODS

- We exported regulatory information on all CONITEC decision outcomes since 2020 from the CONITEC website
- Next, we isolated data related to drug submissions and categorized them by therapeutic area
- We then analyzed incorporations and denials across each category

RESULTS

CONITEC has completed 341 assessments since 2020, 85% (289) of which were new health technology evaluations, 6% (20) indication expansions and 9% (32) re-evaluations.

In total, 46% (158) of assessments resulted in a positive recommendation and inclusion on the positive reimbursement list (RENAME), while the remaining 54% (183) were not recommended or excluded from RENAME.

The number of submissions each year generally increases over time, with an exception in 2023, where a dip in assessment volumes was observed.





Figure 1: Total final CONITEC recommendations 2020 - 1H 2025



Total Recommendations Per Year					
51	82	69	42	69	32

Figure 2: Final CONITEC recommendations by year

Incorporate into SUS Expand access within SUS Deny incorporation into SUS Limit access within SUS

Table 1: Top 5 TA classes ranked by proportion of CONITEC submissions with success rates between 2020 - 1H 2025

TA Class	% Submissions	Success Rate
Oncology	19%	35%
Immunology	17%	35%
Infectious Diseases	15%	62%
Rare genetic disorders	11%	35%
Cardiology/Hematology	6%	23% / 52%
Other	26%	Mixed

The largest proportion of new technology evaluations are in oncology (19%), followed by immunology (17%), infectious diseases (15%) and rare genetic diseases (11%), with the remaining disease areas accounting for less 10% of evaluations.

In contrast, the highest approval rates in areas with more than five assessments have been observed in endocrinology (65%) and infectious diseases (62%).

CONCLUSIONS

- Over the past five years, CONITEC has prepared an increasingly higher number of final recommendations for Brazil’s public health system, with a clear alignment to the MoH’s public health initiatives
- There exists however, a potential misalignment between trends in pharmaceutical research and development focus and new technology submissions and CONITEC’s final recommendations, with positive review probabilities concentrating around endocrinal and infectious therapeutic areas rather than in oncology and immunology

References: Recomendações da Conitec, September 19, 2025

Abbreviations: CONITEC: Brazilian Health Technology Assessment Body; SUS: Brazilian Universal Healthcare System; TA:Therapeutic Area; 1H: First Half; MoH: Ministry of Health; HTA: Health Technology Assessment